The stock of Repligen Corp (RGEN) has seen a -10.95% decrease in the past week, with a -6.85% drop in the past month, and a -18.87% decrease in the past quarter. The volatility ratio for the week is 1.23%, and the volatility levels for the past 30 days are at 2.67% for RGEN. The simple moving average for the past 20 days is -5.49% for RGEN’s stock, with a -17.41% simple moving average for the past 200 days.
Is It Worth Investing in Repligen Corp (NASDAQ: RGEN) Right Now?
The 36-month beta value for RGEN is at 1.11. Analysts have varying views on the stock, with 10 analysts rating it as a “buy,” 4 rating it as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for RGEN is 53.12M, and currently, shorts hold a 6.49% of that float. The average trading volume for RGEN on June 20, 2025 was 833.42K shares.
RGEN) stock’s latest price update
Repligen Corp (NASDAQ: RGEN) has seen a decline in its stock price by -2.87 in relation to its previous close of 121.01. However, the company has experienced a -10.95% decline in its stock price over the last five trading sessions. businesswire.com reported 2025-06-16 that BOSTON–(BUSINESS WIRE)–908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (Nasdaq: RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company’s Chief Technology Officer & Vice President of Research & Development from February 2.
Analysts’ Opinion of RGEN
Many brokerage firms have already submitted their reports for RGEN stocks, with Wolfe Research repeating the rating for RGEN by listing it as a “Outperform.” The predicted price for RGEN in the upcoming period, according to Wolfe Research is $160 based on the research report published on April 29, 2025 of the current year 2025.
Evercore ISI, on the other hand, stated in their research note that they expect to see RGEN reach a price target of $155. The rating they have provided for RGEN stocks is “In-line” according to the report published on March 18th, 2025.
TD Cowen gave a rating of “Buy” to RGEN, setting the target price at $200 in the report published on February 10th of the current year.
RGEN Trading at -8.49% from the 50-Day Moving Average
After a stumble in the market that brought RGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -35.60% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at RGEN starting from Hunt Anthony, who sale 26,447 shares at the price of $123.71 back on May 15 ’25. After this action, Hunt Anthony now owns 109,854 shares of Repligen Corp, valued at $3,271,688 using the latest closing price.
Hunt Anthony, the Director of Repligen Corp, proposed sale 26,447 shares at $128.34 during a trade that took place back on May 15 ’25, which means that Hunt Anthony is holding shares at $3,394,208 based on the most recent closing price.
Stock Fundamentals for RGEN
Current profitability levels for the company are sitting at:
- -0.06 for the present operating margin
- 0.43 for the gross margin
The net margin for Repligen Corp stands at -0.04. The total capital return value is set at -0.01. Equity return is now at value -1.16, with -0.81 for asset returns.
Based on Repligen Corp (RGEN), the company’s capital structure generated 0.26 points at debt to capital in total, while cash flow to debt ratio is standing at 0.21. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is -2.18.
Currently, EBITDA for the company is 82.1 million with net debt to EBITDA at -0.11. When we switch over and look at the enterprise to sales, we see a ratio of 10.21. The receivables turnover for the company is 4.38for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.79.
Conclusion
In conclusion, Repligen Corp (RGEN) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
